THE PREDICTORS OF UNDIAGNOSED DYSGLYCAEMIA IN PATIENTS WITH ESTABLISHED RHEUMATOID ARTHRITIS

Hazlyna Baharuddin1, Nur Ami Eddy Warman1, Azmililah Rosman2, Thuhaairah Abdul Rahman3, Nurhuda Ismail3, Rohana Abdul Ghani1. 1Universiti Teknologi MARA, Department of Medicine, Sungai Buloh, Malaysia; 2Hospital Selayang, Department of Medicine, Batu Caves, Malaysia; 3Universiti Teknologi MARA, Department of Pathology, Sungai Buloh, Malaysia.

Background: Rheumatoid arthritis (RA) is a chronic autoimmune disease that causes joint damage, deformity, and pain. This can lead to loss of functionality and mobility, which entails a decrease in the quality of life and the possible occurrence of anxiety and depressive disorders[1].

Objectives: To determine the prevalence of dysglycaemia (T2DM, impaired fasting glucose (IFG) and impaired glucose tolerance (IGT)) and the factors associated with dysglycaemia in patients with established RA.

Methods: This is a cross-sectional study conducted in a rheumatology centre in Malaysia. Patients with established RA aged 30 years or more were included. Exclusion criteria were overlap syndrome, pre-existing diabetes or pre-diabetes, pregnant and within 6 weeks of post-partum period. An oral glucose tolerance test (OGTT) was performed for all patients. Comparison of various factors between dysglycaemia and normoglycaemia were analysed. Multivariate analysis was performed using logistic regression analysis to ascertain the true effects of significant factors found on univariate analysis.

Results: The mean age of patients was 57.2 ± 8.1 years and 87.7% were female. Of 155 patients included in this study, 55 (35.5%) were found to have dysglycaemia; 40 (72.7%) had IGT, 11 (20%) had T2DM, 3 had IFG and IGT (5.5%) and 1 had IFG (1.8%). Significant factors between dysglycaemia and normoglycaemia is tabulated in Table 1. The predictors of dysglycaemia were previous or current smoker, and raised triglycerides.

Conclusion: One third of 155 patients had dysglycaemia and majority had IGT. The predictors of dysglycaemia in patients with established RA aged 30 years and more, were previous or current smoker and raised triglycerides.

Table 1. Factors investigated for differences between dysglycaemia and normoglycaemia.

<table>
<thead>
<tr>
<th>Risk factors</th>
<th>Dysglycaemia n=55</th>
<th>Normoglycaemia n=100</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Previous or current smoker, n (%)</td>
<td>7 (13.0)</td>
<td>3 (3.0)</td>
<td>0.02</td>
</tr>
<tr>
<td>Waist circumference (cm), mean ± SD</td>
<td>89.9 ± 12.5</td>
<td>83.1± 9.6</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Weight (kg), mean ± SD</td>
<td>65.5 ± 12.3</td>
<td>60.7 ± 10.6</td>
<td>0.01</td>
</tr>
<tr>
<td>Systolic blood pressure (mmHg), mean ± SD</td>
<td>134.5 ± 17.5</td>
<td>126.2 ± 18.1</td>
<td>0.04</td>
</tr>
<tr>
<td>Diastolic blood pressure (mmHg), mean ± SD</td>
<td>79.7 ± 8.7</td>
<td>76.3 ± 10.5</td>
<td>0.04</td>
</tr>
<tr>
<td>High density lipoprotein (mmol/L), mean ± SD</td>
<td>1.4 ± 0.3</td>
<td>1.5 ± 0.4</td>
<td>0.02</td>
</tr>
<tr>
<td>Triglycerides (mmol/L), mean ± SD</td>
<td>1.3 ± 0.5</td>
<td>1.1 ± 0.5</td>
<td>&lt;0.01</td>
</tr>
</tbody>
</table>

REFERENCES


Acknowledgement: We would like to thank the Rheumatology team in Hospital Selayang and the Director General of Ministry of Health Malaysia for allowing us to conduct this study in Hospital Selayang.

Disclosure of Interests: None declared


QUALITY OF LIFE IN WOMEN WITH RHEUMATOID ARTHRITIS DEPENDING ON ANXIETY AND DEPRESSION

Ekaterina Egorova, Nataya Nikitina, Andrey Rebrov, Saratov State Medical University named V. I. Razumovsky, Ministry of Health of Russia, Hospital Therapy Department, Saratov, Russian Federation

Background: Rheumatoid arthritis (RA) is a chronic autoimmune disease that causes joint damage, deformity, and pain. This can lead to loss of functionality and mobility, which entails a decrease in the quality of life and the possible occurrence of anxiety and depressive disorders[1].

Objectives: Assess the quality of life in women with RA, depending on the severity of anxiety and depression.

Methods: The study included 104 women with reliable RA according to the ACR1987 and/or EULAR/ACR2010 criteria (mean age 53.7 ± 10.9 years, mean duration of RA – 10.1 [4;14] years, DAS28 – 4.96 [4.27,5.77]). An assessment of the severity of anxiety and depression was conducted using a questionnaire for the hospital scale of depression and anxiety (HADS). Evaluation of the quality of life of patients with rheumatoid arthritis was performed using the EQ-SD index. Depending on the degree of functional impairment, according to the HAD questionnaire, were regarded as minimal (0.5-1 point), moderate (1.2-3 points), the population norm was 0-0.5 points. The severity of pain was determined by VAS: no pain (0–4 mm), mild pain (5–44 mm), moderate pain (45–74 mm), severe pain (75–100 mm). Statistical processing was performed using the program STATISTICA 10.0.

Results: The frequency of occurrence of anxiety-depressive disorders in patients with RA was determined: clinically significant anxiety was detected in 20 (19.2%) patients, depression - in 19 (17.3%); subclinical anxiety - in 26 (25%), depression - in 27 (25.9%) patients; the absence of reliably expressed symptoms of anxiety in 58 (55.8%) patients, depression - in 59 (56.8%) patients. HAD functional impairment was absent in 11 (10.6%) patients, minimal impairment was detected in 20 (19.2%), moderate - in 52 (50%), and pronounced in 21 (20.2%) patients.

Severe pain in the VAS was noted by 38 (36.6%) patients, moderate - in 51 (48%), in 15 (14.4%) patients the pain syndrome was weakly expressed.

The EQ and SD-indices for women were 1.26 [0.88;1.75] and 0.41 [0.07;0.59], respectively. The relationships between the HAD and EQ-SD indices (r = 0.67, p <0.05), the HAD index and the age of the patients (r = 0.33, p <0.05), and the duration of the disease (r = 0.29, p <0.05), ESR indicator (r = 0.28, p <0.05), CRP (r = 0.37, p <0.05), the level of pain in VAS (r = 0.4, p <0.05), DAS28 index (r = 0.32, p <0.05), anxiety severity (r = 0.22, p <0.05), depression severity (r = 0.31, p < 0.05). The relationship between the EQ-SD index and the age of the patients (r = 0.29, p <0.05), with the duration of the disease (r = 0.22, p <0.05), CRP (r = 0.32, p <0.05), the level of pain in VAS (r = 0.45, p <0.05), the severity of anxiety (r = 0.28, p <0.05), the severity of depression (r = 0.35, p <0.05).

To clarify the relationship between the quality of life of patients and the level of depression and anxiety, two groups were identified: no anxiety-depressive disorders (N = 43) and the second group with their presence (N = 30). The EQ-SD index in the first group was 0.59 [0.52; 0.62] and in the group with anxiety and depressive disorders it was 0.27 [0.02; 0.52] (p = 0.005). The HAD index significantly differed in women without anxiety and depressive disorders 1.0 [0.625; 1.5] with the index in the other group 1.75 [1.0; 2.125] (p = 0.01).

Conclusion: Thus, every fifth patient with RA suffers from clinically significant anxiety and depression; subclinical anxiety and depression were found in 25% of patients with RA. Interrelations between the indicators of quality of life of patients with RA and the patient’s age, duration, activity of RA, severity of anxiety and depressive disorders.
REFERENCES


Disclosure of Interests: None declared

AB0315 EVALUATION OF SLEEP QUALITY, FATIGUE AND SEXUAL PROFILE IN ELDERLY PATIENTS WITH RHEUMATOID ARTHRITIS

ACHEK Mohamed Amine EL, Amel Farhat, Saoussen Zhour, Ismail Bejia, Mongi Touzi, Mahbouba Jguirim, Naceur Bergaoui. Fattouma Bourguiba University Hospital, Rheumatology, Monastir, Tunisia

Background: People over the age of 60 with rheumatoid arthritis (RA) often complain of fatigue, which is considered an extra-articular symptom. This problem has a multidimensional character and sounds on the quality of sleep and on the sexual profile.

Objectives: Our study consists in assessing the prevalence of fatigue and studying the quality of sleep and the sexual profile of patients over 60 years of age with RA compared to subjects suffering from the same illness of younger age.

Methods: This is a prospective study involving 100 patients at the Rheumatology department of Fattouma Bourguiba university hospital in Monastir over a period of 6 months: 40 patients more than 60 years of age with RA compared with 60 patients with RA of younger age.

Data collection was based on scales and specific questionnaires (Visual Analogue Fatigue Scale (VAS-F), Multidimensional Fatigue Inventory (MFI-20), Pittsburgh Sleep Quality Index (PSQI), Female sexual Function Index (FSFI), Sexual Health Inventory for Men (SHIM)).

Results: The average age was 55.8 years [25-84]. The most represented age group was over 60 (40%). The sex ratio was 5.6.

73% of our patients were married and 81% had children with an average number of 3 children in charge and extremes between 1 and 9. Fatigue, sleep quality and sexual profile were analyzed comparatively and respectively between the 2 groups (1st group >60 and second <60 years). The average of the VAS-F was 26.55 compared to 53.5. Fatigue (via MFI-20) was present in all its domains in our patients. General fatigue and physical fatigue were the highest, averaging 13.98 vs. 13.07 and 12.98 vs. 12.33 respectively. Sleeping insomnia (PSQI= 5) was found with the same proportion of 65% in both groups. Low sleep quality was found in 90% versus 93%. A sleep latency> 31 minutes was found in 37.5% against 30%. Sleep duration <6 hours per night was found in 52.5% versus 50%. Sleep efficiency <85% was found at an equal percentage of 75%. Sleep disorders> 10 times in the last 4 weeks were found at an equal percentage of 15%. Regular female sexual activity was found in 42.5% versus 71% and dysfunction (FSFI<=6.55) was noted in 35% versus 63.3%. Regular male sexual activity was found in 54.5% against 75% and mild erectile dysfunction (SHIM=21) was noted in 83.3% against 20%.

Conclusion: A multidimensional approach is needed to explore the different components of fatigue, sleep quality and sexual profile in patients with RA and its very diverse consequences. This should lead to an improvement in the quality of life in the current medical practice.

Disclosure of Interests: None declared

AB0316 ESTABLISHED SERONEGATIVE RHEUMATOID ARTHRITIS IS CONSIDERED A MILD FORM OF THE DISEASE. ALSO WILL IT BE THE SAME REGARD FOR VERY EARLY SERONEGATIVE RHEUMATOID ARTHRITIS?

Fajardo Hermosillo Luís Daniel. IMSS, Hospital Regional N 110, Rheumatology, Guadalajara, Mexico

Background: Established Seronegative Rheumatoid Arthritis (ESNRA) is considered a mild form of the disease with a good prognosis and response to therapy compared with seropositive (SP) form [1]. Lately evidence indicates that seronegative (SN) form of arthritis in early stage is serious and should not be underestimated in terms of disease activity, response to therapy and radiographic damage [2,3,4]. At present, the influence of SN status of clinical course and treatment choice in very early stages, in other words less than 3 months from time at onset of disease, is still controversial [5].

Objectives: To evaluate demographical, clinical and treatment differences between Very Early Seronegative Rheumatoid Arthritis (VESNRA) and Very Early Seropositive Rheumatoid Arthritis (VESPA) in a Mexican cohort.

Methods: 64 patients with Very Early Rheumatoid Arthritis ([VERA], < 3 months from time at onset of clinical manifestations) that fulfilled ACR/ EULAR 2010 criteria (>18 years) from a Mexican cohort recruited from 2015 to 2018 were examined and followed to 3, 6 and 12 months. Patients without presence of rheumatoid factor (RF) and antinuclear protein antibodies (ACPA) were considered SN. Demographic factors, clinical features, disease activity measured using DAS28, functional status evaluated using HAQ, comorbidities and pharmalogic treatments were examined for patients with VESNRA and VESPA. Charlson’s clinical comorbidity index was used to analyze comorbidities. Chi-square and Student-t test was performed by univariate analysis and logistic regression was used by multivariate analysis, both were adjusted for age and gender. Statistical test were conducted at 5% level of significance.

Results: Of 64 patients with VERA 79% were women. The mean age [standard deviation (SD)] was 49.8 (13.5) years. The mean of time at onset of VERA (SD) was 77.8 (15.5) days. A total of 20 (31.2%) patients had VESNRA. In the univariable analyses VESNRA patients were more likely to have minor disease activity and better functional status during their follow-up to 3, 6 and 12 months [Table 1]. Moreover, VESNRA patients were more likely to present lesser work disability, lower comorbidities including fibromyalgia, to use fewer sulfasalazine, leflunomide, biologic agents and corticosteroids. As expected, the modified Charlson’s comorbidity index score was lower in VESNRA patients through all their follow-up. In multivariable analyses less frequently use of corticosteroids (OR 0.68, 95% CI 0.42-0.88, p<0.001) remained significant in VESNRA patients.

Conclusion: This study suggests that in very early stage of disease, SN form presents minor disease activity, better functional status, lower comorbidities, also require less aggressive therapy using biologic agents and corticosteroids than SP form in the course of one year. By these clinical and therapeutic differences should be considered VESNRA a mild form of the disease like as ESNRA. These observations must be confirmed in larger studies with further follow-up.

REFERENCES


Table 1. Disease activity and functional status in VESNRA and VESPA Patients

<table>
<thead>
<tr>
<th>Feature</th>
<th>VERA</th>
<th>VESNRA</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Disease activity (DAS28), mean score (SD)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>5.99 (0.85)</td>
<td>5.09 (0.76)</td>
<td>NS</td>
</tr>
<tr>
<td>3 months</td>
<td>3.43 (1.09)</td>
<td>2.42 (0.85)</td>
<td>0.003</td>
</tr>
<tr>
<td>6 months</td>
<td>2.76 (0.97)</td>
<td>2.04 (0.72)</td>
<td>0.008</td>
</tr>
<tr>
<td>12 months</td>
<td>2.25 (0.57)</td>
<td>1.74 (0.22)</td>
<td>0.002</td>
</tr>
<tr>
<td>Functional status (HAQ), mean score (SD)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>2.19 (0.30)</td>
<td>1.72 (0.28)</td>
<td>NS</td>
</tr>
<tr>
<td>3 months</td>
<td>1.86 (0.32)</td>
<td>1.29 (0.33)</td>
<td>0.007</td>
</tr>
<tr>
<td>6 months</td>
<td>1.49 (0.42)</td>
<td>0.87 (0.35)</td>
<td>0.011</td>
</tr>
<tr>
<td>12 months</td>
<td>0.99 (0.36)</td>
<td>0.56 (0.17)</td>
<td>0.025</td>
</tr>
</tbody>
</table>

VESNRA: Very Early Seronegative Rheumatoid Arthritis; VESPA: Very Early Seropositive Rheumatoid Arthritis; SD: Standard deviation; NS: Not significant

Disclosure of Interests: None declared

AB0317 THE EFFECT OF ANEMIA ON THE CARDIAC FUNCTION IN PATIENTS WITH RHEUMATOID ARTHRITIS

Lutsiaiia Feiskhanova1, Svetlana Lapshina1, Abina Yusupova2, Aigul Akhmetzianova2. 1Kazan State Medical University, Kazan, Russian Federation; 2Kazan State Medical University, Kazan, Russian Federation

Background: Rheumatoid arthritis (RA) is a chronic disease that is characterized by defeat of the musculoskeletal system and is often accompanied by the anemia.

Disclosure of Interests: None declared